Geneva, November 10, 2010: Ares Life Sciences, an investment firm established by the
Bertarelli family to invest in the healthcare industry, announces that, it has today signed an
agreement to acquire Wendel’s equity interest in Stallergenes, representing 45.86% of the
share capital and voting rights of Stallergenes, at a price of €59.00 per share. This signature
follows the positive advice of Stallergenes’ Works Council.
The closing of the transaction will occur early next week.
Following the closing Ares Life Sciences will file a mandatory takeover offer for the
remaining outstanding shares of Stallergenes, at the same price of €59.00 per share in cash.
Ares Life Sciences does not plan to effect a squeeze out or delisting of the company
following this offer.
Moelis & Company and Centerview Partners are acting as lead financial advisors and
Deutsche Bank as financial advisor to Ares Life Sciences, while Skadden, Arps, Slate, Meagher
& Flom LLP is legal advisor.
About Ares Life Sciences
Ares Life Sciences is a healthcare-focused investment firm, whose financial backer is the
Bertarelli family. Its strategy is to focus on key life sciences sectors, mainly: pharmaceuticals
and biotechnology, medical diagnostics, and medical technology. Ares Life Sciences has a
long-term view on investments and a core element of its investment strategy is to make
available to its portfolio companies the collective experience and network of its team. Ares
Life Sciences’ portfolio currently includes investments in Euromedic, Esaote, Santhera and
Wendel is one of Europe's leading listed investment firms. The Group invests in France and
abroad, in companies that are leaders in their industry: Bureau Veritas, Legrand, Saint-
Gobain, Materis, Deutsch, Stallergenes, Oranje-Nassau and Stahl. Wendel plays an active
role as an industry shareholder. It implements long-term development strategies, which 2
involve boosting growth and profitability of companies so as to enhance their leading market
positions. Wendel’s consolidated 2009 sales totalled €4.9 billion. Wendel is listed on Eurolist
by Euronext Paris. Standard & Poor’s rating: Long term BB-, stable outlook - Short term B
since July 19, 2010.
Stallergenes is a European biopharmaceutical laboratory specialising in treatments by
immunotherapy for the prevention and treatment of allergy-related respiratory conditions,
such as rhino conjunctivitis, rhinitis and allergic asthma. A pioneer and a leader in
immunotherapy treatments by sublingual administration, Stallergenes dedicated more than
20% (gross) of its sales in 2009 to its Research and Development activities, which are
primarily directed at developing a new therapeutic range enabling the provision of
immunotherapy treatments by sublingual tablets. Stallergenes achieved 2009 sales of €193
million, with over 500,000 patients treated with Stallergenes products.
For more information, please contact
Christophe Lamps - Dynamics Group
Rue des Caroubiers 21, Geneva, Switzerland
Tel:+41 22 308 62 20 Mob: +41 79 476 26 87 Fax: +41 22 308 62 36
Agnes Catineau/Marie-Laurence Bouchon
Tel: +33 1 53 96 83 83
Tel: +44 20 7396 5312
Paco Latorre - Ares Life Sciences
Avenue Guiseppe Motta 31-33, CH- 1211 Geneva 20, Switzerland
Tel: +41 79 5716207